Lifecore BiomedicalLFCR -3.78%55 Quick Ratio is 2.41 as of Mar. 2026, which is 180% above its 10-year median of 0.86. GuruFocus rates LFCR with a GF Score™ of 55/100 and a GF Value™ of $6.52 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 994 Drug Manufacturers companies, Lifecore Biomedical ranks better than 69.62% on this metric.
Lifecore Biomedical has a quick ratio of 2.41. It generally indicates good short-term financial strength.
The historical rank and industry rank for Lifecore Biomedical's Quick Ratio or its related term are showing as below:
LFCR'
s Quick Ratio Range Over the Past 10 Years
Min: 0.25 Med: 0.86 Max: 2.41
Current: 2.41
During the past 13 years, Lifecore Biomedical's highest Quick Ratio was 2.41. The lowest was 0.25. And the median was 0.86.
LFCR's Quick Ratio is ranked better than 69.62% of 994
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs LFCR: 2.41
Lifecore Biomedical (NAS:LFCR) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Lifecore Biomedical Quick Ratio Related Terms
Lifecore Biomedical Quick Ratio Historical Data
* Premium members only.
The historical data trend for Lifecore Biomedical's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lifecore Biomedical Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Lifecore Biomedical's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Lifecore Biomedical's Quick Ratio for the fiscal year that ended in May. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lifecore Biomedical (LFCR) has a Quick Ratio of 2.41 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Lifecore Biomedical and its competitors. This is 180% above median its historical median of 0.86. Over the past decade, Lifecore Biomedical's Quick Ratio has ranged from 0.25 to 2.41. According to the industry distribution chart, Lifecore Biomedical ranks #302 out of 994 companies in the Drug Manufacturers industry, placing it in the top 30.4%.
Is Lifecore Biomedical's Quick Ratio too high?
Lifecore Biomedical's current Quick Ratio of 2.41 is 180% above median its 10-year median of 0.86. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 2.41. The Drug Manufacturers industry median Quick Ratio is 1.45. Lifecore Biomedical's value of 2.41 is 66.2% above this industry median. Based on the distribution chart, Lifecore Biomedical ranks #302 out of 994 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Lifecore Biomedical has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lifecore Biomedical's Quick Ratio compare to ANIK and DERM?
According to the Drug Manufacturers industry distribution chart, Lifecore Biomedical ranks #302 out of 994 companies for Quick Ratio. This puts Lifecore Biomedical in the upper half of its industry. The industry median Quick Ratio is 1.45. Lifecore Biomedical's value of 2.41 is 66.2% above this benchmark. Historically, Lifecore Biomedical's own Quick Ratio has ranged from 0.25 to 2.41 over the past decade. While the company's 10-year median is 0.86 vs. the industry median of 1.45, Lifecore Biomedical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 994 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lifecore Biomedical's current Quick Ratio of 2.41 is 66.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Lifecore Biomedical and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lifecore Biomedical's current Quick Ratio is 2.41, which is 180% above median its own 10-year median of 0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifecore Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lifecore Biomedical (LFCR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.52, compared to a current price of $4.97 — trading 23.8% below its estimated fair value. The current Quick Ratio is 2.41, which is 180% above median its 10-year median of 0.86 and 66.2% above the Drug Manufacturers industry median of 1.45. Lifecore Biomedical's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Lifecore Biomedical (LFCR), the current Quick Ratio is 2.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lifecore Biomedical (LFCR) Overvalued in 2026?
Based on GuruFocus' analysis, Lifecore Biomedical stock appears to be undervalued.
The current stock price of $4.97 is trading 23.8% below its estimated GF Value™ of $6.52.
GuruFocus considers Lifecore Biomedical to be Modestly Undervalued.
Key valuation signals for LFCR:
Quick Ratio: 2.41 (180% above median its 10-year median of 0.86)
GF Value™: $6.52 vs. price of $4.97 (23.8% below fair value)
Industry Position: 66.2% above the Drug Manufacturers median (#302 of 994)
No single metric tells the full story. See the LFCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
55GF Score
Get the complete analysis for LFCR
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LFCR has been successfully added to your 
